Sauvie Therapeutics

Sauvie Therapeutics is a biotechnology company focused on developing next-generation immunotherapies for the treatment of cancer. The company utilizes a proprietary platform to engineer multi-specific antibodies that target the CD47-SIRPα pathway, a critical "don't eat me" signal used by cancer cells to evade the immune system. Unlike earlier CD47 inhibitors, Sauvie's candidates are designed for conditional activation, aiming to minimize off-target effects such as anemia and hemagglutination by requiring the presence of specific tumor-associated antigens. Currently in the pre-clinical stage, the company is advancing a pipeline of biologics intended to treat both solid tumors and hematologic malignancies. Sauvie is headquartered in Oregon and is led by an experienced management team with a track record in oncology drug development.